Overview

Opioid Antagonism in Hypogonadotropic Hypogonadism

Status:
Recruiting
Trial end date:
2025-02-28
Target enrollment:
Participant gender:
Summary
The goal of this study is to evaluate the effects of opioid antagonists on the hypothalamic-pituitary-gonadal axis in subjects with idiopathic hypogonadotropic hypogonadism (HH).
Phase:
Phase 2
Details
Lead Sponsor:
Stephanie B. Seminara, MD
Treatments:
Naloxone
Prolactin Release-Inhibiting Factors